Curis Lifesciences IPO Financials
The Curis Lifesciences IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Dec 2024, Curis Lifesciences Limited reported assets of ₹50.12 crore, revenue of ₹36.91 crore, and a profit after tax (PAT) of ₹5.3 crore. The company had a net worth of ₹15.53 crore and reserves & surplus of ₹9.59 crore, and total borrowings are 16.16 crore.
Revenue decreased by 2.76% in 31 Mar 2024 and increased by 1.39% in 31 Mar 2023 and decreased by 34.71% in 31 Mar 2022, while Profit After Tax (PAT) declined by 5.09% in 31 Mar 2024 and declined by 63.22% in 31 Mar 2023 and declined by 73.51% in 31 Mar 2022, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Curis Lifesciences Limited Financials (₹ in Crores)
| Particular | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 50.12 | 33.82 | 29.67 | 27.4 |
| Revenue | 36.91 | 35.89 | 36.39 | 23.76 |
| Profit After Tax | 5.3 | 5.03 | 1.85 | 0.49 |
| Net Worth | 15.53 | 5.97 | 0.95 | 0.9 |
| Reserve & Surplus | 9.59 | 5.47 | 0.45 | -1.4 |
| Total Borrowings | 16.16 | 17.09 | 16.19 | 17.62 |
EPS Pre
0.00%
EPS Post
0.00%
P/E Pre
0.00
P/E (Post Issue)
0.00x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Curis Lifesciences Limited?
Curis Lifesciences Limited reported revenue of ₹36.91 crore as of 31 Dec 2024. Revenue figures from the Curis Lifesciences IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Curis Lifesciences Limited?
Curis Lifesciences Limited reported a Profit After Tax (PAT) of ₹5.3 crore as of 31 Dec 2024. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Curis Lifesciences Limited?
Curis Lifesciences Limited has a Price-to-Earnings (P/E) ratio of 0x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.